Glutathione S-transferase polymorphisms and survival from head and neck cancer

Head and Neck

Volumn 27, Issue 3, 2005, Pages 232-242

  Geisler, Stacy A ^a   Olshan, Andrew F ^b   Cai, Jianwen ^b   Weissler, Mark ^c   Smith, Joanna ^b   Bell, Douglas ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cancer outcomes; Genetics; Longevity; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN; DNA; GLUTATHIONE TRANSFERASE;

ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; TOBACCO;

CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 14644429064     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20141     Document Type: Article

References (55)

1. Landis S, Murray T, Bolden S, Wingo P. Cancer statistics. CA 1999;49:8-31.
2. Olshan A, Watson M, Weissler M, Bell D. XRCC1 polymorphisms and head and neck cancer. Cancer Lett 2002;178:181-186.
3. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-1586.
4. Shin DM, Lee JS, Lippman SM, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-529.
5. Geisler S, Olshan A. GSTM1, GSTT1 and risk of head and neck cancer: a mini-HuGE review. Am J Epidemiol 2001;154:95-105.
6. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000;463:247-283.
7. Pemble S, Schroeder K, Spencer S, et al. Human glutathione S-transferase theta (GSTT1):cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-276.
8. Hou C, Patel R, Laskin A, Barnabe B. Epoxidation of short-chain alkanes by resting-cell suspensions of propane-grown bacteria. Appl Environ Microbiol 1983;46:171-177.
9. Rebbeck T. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-743.
10. Hengstler J, Arand M, Herrero M, Oesch F. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. In: Recent results in cancer research. Heidelberg: Springer-Verlag Berlin: 1998. p 46-83.
11. Harries L, Stubbins M, Forman D, Howard G, Wolf C. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular, and prostate cancer. Carcinogenesis 1997;18:641-644.
12. 105Val polymorphism. Cancer Res 2000;60:5621-5624.
13. Spitz M, Fueger J, Beddingfield N, et al. Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 1989;49:4626-4628.
14. Wang L, Sturgis E, Eicher S, Spitz M, Hong W, Wei Q. Mutagen sensitivity to benzo[a]pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 1998;4:1773-1778.
15. Shen H, Zheng Y, Sturgis E, Spitz M, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183:123-130.
16. Cheng L, Sturgis E, Eicher S, Spitz M, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002;94:393-397.
17. Shen M, Jones I, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998;58:604-608.
18. Yu Z, Chen J, Ford B, Brackley M, Glickman B. Human DNA repair systems: an overview. Environ Mol Mutagen 1999;33:3-20.
19. Lindahl T, Wood R. Quality control by DNA repair. Science 1999;286:1897-1905.
20. Olshan A, Weissler M, Watson M, Bell D. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2000;9:185-191.
21. Chen H, Sandler D, Taylor J, Shore D. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996;347:295-297.
22. Watson M, Stewart R, Smith G, Bell D. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998;19:275-280.
23. Lunn R, Langlois R, Hsieh L, Thompson C, Bell D. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59:2557-2561.
24. Hayes J, Pulford D. The glutathione S-transferase supergene family: regulation of GST* and the contribution of the isoenzymes to cancer chemoprevention and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
25. Schroder K, Wiebel F, Reich S, Dannappel D, Bolt H, Hallier E. Glutathione-S-transferase (GST) theta polymorphism influences background SCE rate. Arch Toxicol 1995;69:505-507.
26. Muller M, Kramer A, Angerer J, Hallier E. Ethylene oxide-protein adduct formation in humans: influence of glutathione-S-transferase polymorphisms. Int Arch Occup Environ Health 1998;71:499-502.
27. Li R, Boerwinkle E, Olshan A, et al. Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis 2000;149:451-462.
28. Li R, Folsom A, Sharrett A, Couper D, Bray M, Tyroler H. Interaction of the glutathione S-transferase genes and cigarette smoking on the risk of lower extremity arterial disease: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001;154:729-738.
29. Olshan A, Li R, Pankow J, et al. Risk of atherosclerosis: interaction of smoking and glutathione S-transferase genes. Epidemiology 2003;14:321-327.
30. Trizna Z, Clayman GL, Spitz MR, Briggs KL, Goepfert H. Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am J Surg 1995;170:499-501.
31. Deakin M, Elder J, Hendrickse C, et al. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric, and colorectal cancers. Carcinogenesis 1996;17:881-884.
32. Jahnke V, Matthias C, Fryer A, Strange R. Glutathione S-transferase and cytochrome-P-450 polymorphism as risk factors for squamous cell carcinoma of the larynx. Am J Surg 1996;172:671-673.
33. Hung H, Chuang J, Chien Y, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 1997;6:901-905.
34. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev 1998;7:19-23.
35. Matthias C, Bockmuhl U, Jahnke V, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1, and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 1998;8:91-100.
36. Ophuis M, van Lieshout E, Roelofs H, Peters W, Manni J. Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer 1998;82:936-943.
37. Worrall S, Corrigan M, High A, et al. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 1998;8:433-439.
38. Cheng L, Sturgis E, Eicher S, Char D, Spitz M, Wei Q. Glutathione-S-transferase polymorphisms and risk of squamous cell carcinoma of the head and neck. Int J Cancer 1999;84:220-224.
39. Jourenkova-Mironova N, Voho A, Bouchardy C, et al. Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer 1999;81:44-48.
40. Katoh T, Kaneko S, Kohshi K, et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 1999;83:606-609.
41. McWilliams J, Evans A, Beer T, Andersen P, Cohen J, Henner W. Genetic polymorphisms in head and neck cancer risk. Head Neck 2000;22:609-617.
42. Ko Y, Abel J, Harth V, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398-4404.
43. To-Figueras J, Gene M, Gomez-Catalan J, et al. Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. Cancer Lett 2002;187:95-101.
44. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol Head Neck Surg 2003;128:674-680.
45. Hanna E, MacLeod S, Vural E, Lang N. Genetic deletions of glutathione-S-transferase as a risk factor in squamous cell carcinoma of the larynx: a preliminary report. Am J Otolaryngol 2001;22:121-123.
46. Welfare M, Adeokun A, Bassendine M, Daly A. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999;8:289-292.
47. Reid B, Alberg A, Klassen A, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer 2001;92:2109-2116.
48. Reid B, Alberg A, Klassen A, Koch W, Samet J. The American Society of Anesthesiologist's class as a comorbidity index in a cohort of head and neck cancer surgical patients. Head Neck 2001;23:985-994.
49. Reid B, Alberg A, Klassen A, et al. A comparison of three comorbidity indexes in a head and neck cancer population. Oral Oncol 2002;38:187-194.
50. Gleich L, Collins C, Gartside P, et al. Therapeutic decision making in stages III and IV head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:26-35.
51. Piccirillo J, Lacy P, Basu A, Spitznagel E. Development of a new head and neck cancer-specific comorbidities index. Arch Otolaryngol Head Neck Surg 2002;128:1172-1179.
52. Hathaway B, Johnson J, Piccirillo J, et al. Chemoradiation for metastatic SCCA: role of comorbidity. Laryngoscope 2001;111:1893-1895.
53. Hall S, Rochon P, Streiner D, Paszat L, Groome P, Rohland S. Measuring comorbidity in patients with head and neck cancer. Laryngoscope 2002;112:1988-1996.
54. de Cassia Braga Riberio K, Kowalski L, Latorre Mdo R. Perioperative complications, comorbidities, and survival in oral and oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2003;129:219-228.
55. Murray JE, Ashton LJ, Marshall GM, Michelle H, Norris MD. Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma. In: Rebbeck T, ed. SNPs, haplotypes and cancer: applications in molecular epidemiology. Key Biscayne, FL: American Association for Cancer Research; 2003. p A54.